Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
DOGE co-chair Elon Musk shocked his followers on Christmas Day by posting a tweet of his trimmed-down self in a Santa outfit.
California’s Medicaid program spent the most of all states on GLP-1 coverage, exceeding $1.4 billion, or $118 per enrollee.
Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...
It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...